Skip to main content

Drug for schizophrenia receives a prize

Images

Participants

Image
Emeritus Professor
Tel.+34 93 40 37125
Image
Alumni - Alumni - Research Associate
Tel.+34 93 40 37127

Contact

Image
Section Head of Communication & Outreach
Tel.+34 93 40 37255

IProteos, a spin-off from IRB Barcelona labs and co-funded by the researchers Teresa Tarragó and Ernest Giralt, has received the prize Expoquimia R+D+I for a new drug under development for the treatment of schizophrenia.

Attachment:

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).